1.
Adler, S. M., Girotti, M., & Morilak, D. A. (2020). Optogenetically-induced long term
depression in the rat orbitofrontal cortex ameliorates stress-induced reversal
learning impairment. Neurobiol Stress 13, 100258. 41.
2.
Abe, K., Irie, K., Nakanishi, H., Suzuki, H., & Fujiyoshi, Y. (2018). Crystal structures
of the gastric proton pump. Nature 556, 214-218.
3.
Ahmari, S. E., Spellman, T., Douglass, N. L., Kheirbek, M. A., Simpson, H. B.,
Deisseroth, K., Gordon, J. A., & Hen, R. (2013). Repeated cortico-striatal stimulation
generates persistent OCD-like behavior. Science 340, 1234-1239.
4.
Apicella, A. J., Wickersham, I. R., Seung, H. S., & Shepherd, G. M. (2012). Laminarly
orthogonal excitation of fast-spiking and low-threshold-spiking interneurons in
mouse motor cortex. J Neurosci 32, 7021–7033.
5.
Arborelius, L., Nomikos, G. G., Hertel, P., Salmi, P., Grillner, P., Höök, B. B., Hacksell,
U., & Svensson, T. H. (1996). The 5-HT1A receptor antagonist (S)-UH-301 augments
the increase in extracellular concentrations of 5-HT in the frontal cortex produced
by both acute and chronic treatment with citalopram. Naunyn Schmiedebergs Arch
Pharmacol 353, 630-640.
6.
Asaoka, N., Ibi, M., Hatakama, H., Nagaoka, K., Iwata, K., Matsumoto, M.,
Katsuyama, M., Kaneko, S., & Yabe-Nishimura, C. (2021). NOX1/NADPH Oxidase
Promotes Synaptic Facilitation Induced by Repeated D2 Receptor Stimulation:
Involvement in Behavioral Repetition. J Neurosci 41, 2780-2794.
7.
Asaoka, N., Nishitani, N., Kinoshita, H., Nagai, Y., Hatakama, H., Nagayasu, K.,
Shirakawa, H., Nakagawa, T., & Kaneko, S. (2019). An Adenosine A2A Receptor
Antagonist Improves Multiple Symptoms of Repeated Quinpirole-Induced Psychosis.
eNeuro 6, ENEURO.0366-18.2019.
8.
Austin P. C. (2011). Optimal caliper widths for propensity-score matching when
estimating differences in means and differences in proportions in observational
studies. Pharm Stat 10, 150–161.
9.
Barbon, A., Caracciolo, L., Orlandi, C., Musazzi, L., Mallei, A., La Via, L., Bonini, D.,
Mora, C., Tardito, D., Gennarelli, M., Racagni, G., Popoli, M., & Barlati, S. (2011).
Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA
receptor subunit protein levels. Neurochem Int 59, 896-905.
10. Barr, L. C., Goodman, W. K., McDougle, C. J., Delgado, P. L., Heninger, G. R.,
Charney, D. S., & Price, L. H. (1994). Tryptophan depletion in patients with
51
obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch
Gen Psychiatry 51, 309-317.
11. Barragry, T. P., Blatchford, J. W., 3rd, & Allen, M. O. (1986). Giant gastric ulcers. A
review of 49 cases. Ann Surg 203, 255-259.
12. Baxter, L. R., Jr, Phelps, M. E., Mazziotta, J. C., Guze, B. H., Schwartz, J. M., &
Selin, C. E. (1987). Local cerebral glucose metabolic rates in obsessive-compulsive
disorder. A comparison with rates in unipolar depression and in normal controls.
Archives of general psychiatry 44, 211–218.
13. Benmansour, S., Cecchi, M., Morilak, D. A., Gerhardt, G. A., Javors, M. A., Gould, G.
G., & Frazer, A. (1999). Effects of chronic antidepressant treatments on serotonin
transporter function, density, and mRNA level. J Neurosci 19, 10494-10501.
14. Bergqvist, P. B., Dong, J., & Blier, P. (1999). Effect of atypical antipsychotic drugs on
5-HT2 receptors in the rat orbito-frontal cortex: an in vivo electrophysiological study.
Psychopharmacology 143, 89-96.
15. Berney, A., Sookman, D., Leyton, M., Young, S. N., & Benkelfat, C. (2006). Lack of
effects on core obsessive-compulsive symptoms of tryptophan depletion during
symptom provocation in remitted obsessive-compulsive disorder patients. Biol
Psychiatry 59, 853-857.
16. Beucke, J. C., Sepulcre, J., Talukdar, T., Linnman, C., Zschenderlein, K., Endrass,
T., Kaufmann, C., & Kathmann, N. (2013). Abnormally high degree connectivity of
the orbitofrontal cortex in obsessive-compulsive disorder. JAMA Psychiatry 70, 619629.
17. Bissonette, G. B., Schoenbaum, G., Roesch, M. R., & Powell, E. M. (2015).
Interneurons are necessary for coordinated activity during reversal learning in
orbitofrontal cortex. Biol Psychiatry 77, 454-464.
18. Bloch, M. H., Landeros-Weisenberger, A., Rosario, M. C., Pittenger, C., & Leckman,
J. F. (2008). Meta-analysis of the symptom structure of obsessive-compulsive
disorder. Am J Psychiatry 165, 1532-1542.
19. Bokor, G., & Anderson, P. D. (2014). Obsessive-compulsive disorder. J Pharm Pract
27, 116–130.
20. Bonnet, U., Leniger, T., & Wiemann, M. (2000). Alteration of intracellular pH and
activity of CA3-pyramidal cells in guinea pig hippocampal slices by inhibition of
transmembrane acid extrusion. Brain Res 872, 116–124.
21. Boulougouris, V., Glennon, J. C., & Robbins, T. W. (2008). Dissociable effects of
selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning
in rats. Neuropsychopharmacology 33, 2007-2019.
52
22. Boulougouris, V., & Robbins, T. W. (2010). Enhancement of spatial reversal learning
by 5-HT2C receptor antagonism is neuroanatomically specific. J Neurosci 30, 930938.
23. Burke, K. A., Takahashi, Y. K., Correll, J., Brown, P. L., & Schoenbaum, G. (2009).
Orbitofrontal inactivation impairs reversal of Pavlovian learning by interfering with
'disinhibition' of responding for previously unrewarded cues. Eur J Neurosci 30,
1941-1946.
24. Carta, M., Mameli, M., & Valenzuela, C. F. (2004). Alcohol enhances GABAergic
transmission to cerebellar granule cells via an increase in Golgi cell excitability. J
Neurosci 24, 3746–3751.
25. Casey, J. R., Grinstein, S., & Orlowski, J. (2010). Sensors and regulators of
intracellular pH. Nat Rev Mol Cell Biol 11, 50-61.
26. Celada, P., Puig, M., Amargós-Bosch, M., Adell, A., & Artigas, F. (2004). The
therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci
29, 252-265.
27. Cheng, F. C., Ho, Y. F., Hung, L. C., Chen, C. F., & Tsai, T. H. (2002). Determination
and pharmacokinetic profile of omeprazole in rat blood, brain and bile by
microdialysis and high-performance liquid chromatography. J Chromatogr A 949,
35-42.
28. Courtin, J., Chaudun, F., Rozeske, R. R., Karalis, N., Gonzalez-Campo, C., Wurtz,
H., Abdi, A., Baufreton, J., Bienvenu, T. C., & Herry, C. (2014). Prefrontal
parvalbumin interneurons shape neuronal activity to drive fear expression. Nature
505, 92-96.
29. Dalton, G. L., Wang, N. Y., Phillips, A. G., & Floresco, S. B. (2016). Multifaceted
Contributions by Different Regions of the Orbitofrontal and Medial Prefrontal
Cortex to Probabilistic Reversal Learning. J Neurosci 36, 1996-2006.
30. Delle Chiaie, R., Scarciglia, P., Pasquini, M., Caredda, M., & Biondi, M. (2011).
Aripiprazole augmentation in patients with resistant obsessive compulsive disorder:
a pilot study. Clin Pract Epidemiol Ment Health 7, 107–111.
31. Dias, R., Robbins, T. W., & Roberts, A. C. (1996). Dissociation in prefrontal cortex of
affective and attentional shifts. Nature 380, 69-72.
32. Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015). Antipsychotic
Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant ObsessiveCompulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized,
Placebo-Controlled Trials. Int J Neuropsychopharmacol 18, pyv047.
33. El Mansari, M., & Blier, P. (2005). Responsiveness of 5-HT1A and 5-HT2 receptors in
53
the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. J
Psychiatry Neurosci 30, 268–274.
34. Evans, A. H., & Stegeman, J. R. (2009). Punding in patients on dopamine agonists
for restless leg syndrome. Mov Disord 24, 140–141.
35. Fernández-Morales, J. C., Hua, W., Yao, Y., & Morad, M. (2019). Regulation of Ca2+
signaling by acute hypoxia and acidosis in cardiomyocytes derived from human
induced pluripotent stem cells. Cell calcium 78, 1-14.
36. Franklin, K. B. J. & Paxinos, G. (2007) The Mouse Brain in Stereotaxic Coordinates
3rd edn. Academic Press.
37. Gillan, C. M., Papmeyer, M., Morein-Zamir, S., Sahakian, B. J., Fineberg, N. A.,
Robbins, T. W., & de Wit, S. (2011). Disruption in the balance between goal-directed
behavior and habit learning in obsessive-compulsive disorder. Am J Psychiatry 168,
718-26.
38. Goodwill, H. L., Manzano-Nieves, G., LaChance, P., Teramoto, S., Lin, S., Lopez, C.,
Stevenson, R. J., Theyel, B. B., Moore, C. I., Connors, B. W., & Bath, K. G. (2018).
Early Life Stress Drives Sex-Selective Impairment in Reversal Learning by
Affecting Parvalbumin Interneurons in Orbitofrontal Cortex of Mice. Cell Rep 25,
2299-2307.e4.
39. Graham, D. Y., & Tansel, A. (2018). Interchangeable Use of Proton Pump Inhibitors
Based on Relative Potency. Clin Gastroenterol Hepatol 16, 800-808.e7.
40. Graybiel, A. M., & Rauch, S. L. (2000). Toward a neurobiology of obsessivecompulsive disorder. Neuron 28, 343-347.
41. Gremel, C. M., & Costa, R. M. (2013). Orbitofrontal and striatal circuits dynamically
encode the shift between goal-directed and habitual actions. Nat Commun 4, 2264.
42. Groman, S. M., Keistler, C., Keip, A. J., Hammarlund, E., DiLeone, R. J., Pittenger,
C., Lee, D., & Taylor, J. R. (2019). Orbitofrontal Circuits Control Multiple
Reinforcement-Learning Processes. Neuron 103, 734-746.e3.
43. Hadjas, L. C., Lüscher, C., & Simmler, L. D. (2019). Aberrant habit formation in the
Sapap3-knockout mouse model of obsessive-compulsive disorder. Sci Rep 9, 12061.
44. Hatakama, H., Asaoka, N., Nagayasu, K., Shirakawa, H., & Kaneko, S. (2022). A
selective serotonin reuptake inhibitor ameliorates obsessive-compulsive disorderlike perseverative behavior by attenuating 5-HT2C receptor signaling in the
orbitofrontal cortex. Neuropharmacology 206, 108926.
45. Homayoun, H., & Moghaddam, B. (2008). Orbitofrontal cortex neurons as a common
target for classic and glutamatergic antipsychotic drugs. Proc Natl Acad Sci U S A
105, 18041-18046.
54
46. Honoré, E., Maingret, F., Lazdunski, M., & Patel, A. J. (2002). An intracellular
proton sensor commands lipid- and mechano-gating of the K+ channel TREK-1. The
EMBO J 21, 2968-2976.
47. Invernizzi, R., Bramante, M., & Samanin, R. (1994). Chronic treatment with
citalopram facilitates the effect of a challenge dose on cortical serotonin output: role
of presynaptic 5-HT1A receptors. Eur J Pharmacol 260, 243-246.
48. Izquierdo, A., Darling, C., Manos, N., Pozos, H., Kim, C., Ostrander, S., Cazares, V.,
Stepp, H., & Rudebeck, P. H. (2013). Basolateral amygdala lesions facilitate reward
choices after negative feedback in rats. J Neurosci 33, 4105-4109.
49. Kanaporis, G., Treinys, R., Fischmeister, R., & Jurevičius, J. (2017). Metabolic
inhibition reduces cardiac L-type Ca2+ channel current due to acidification caused
by ATP hydrolysis. PloS one 12, e0184246.
50. Kaneko, S., & Nagashima, T. (2020). Drug Repositioning and Target Finding Based
on Clinical Evidence. Biol Pharm Bull 43, 362–365.
51. Kepecs, A., & Fishell, G. (2014). Interneuron cell types are fit to function. Nature
505, 318-326.
52. Kim, S. E., Kim, M. H., Woo, J., & Kim, S. J. (2020). Dual regulatory effects of
PI(4,5)P2 on TREK-2 K+ channel through antagonizing interaction between the
alkaline residues (K330 and R355-357) in the cytosolic C-terminal helix. Korean J
Physiol Pharmacol 24, 555-561.
53. Kita, K., Albergaria, C., Machado, A. S., Carey, M. R., Müller, M., & Delvendahl, I.
(2021). GluA4 facilitates cerebellar expansion coding and enables associative
memory formation. Elife 10, e65152.
54. Klöckner, U., & Isenberg, G. (1994). Intracellular pH modulates the availability of
vascular L-type Ca2+ channels. J Gen Physiol 103, 647-663.
55. Knight, A. R., Misra, A., Quirk, K., Benwell, K., Revell, D., Kennett, G., & Bickerdike,
M. (2004). Pharmacological characterisation of the agonist radioligand binding site
of 5-HT2A, 5-HT2B and 5-HT2C receptors. Naunyn Schmiedebergs Arch Pharmacol
370, 114-123.
56. Kringelbach M. L. (2005). The human orbitofrontal cortex: linking reward to hedonic
experience. Nat Rev Neurosci 6, 691-702.
57. Külz, A. K., Meinzer, S., Kopasz, M., & Voderholzer, U. (2007). Effects of tryptophan
depletion on cognitive functioning, obsessive-compulsive symptoms and mood in
obsessive-compulsive disorder: preliminary results. Neuropsychobiology 56, 127-131.
58. Li, J. Z., Bunney, B. G., Meng, F., Hagenauer, M. H., Walsh, D. M., Vawter, M. P.,
Evans, S. J., Choudary, P. V., Cartagena, P., Barchas, J. D., Schatzberg, A. F., Jones,
55
E. G., Myers, R. M., Watson, S. J., Jr, Akil, H., & Bunney, W. E. (2013). Circadian
patterns of gene expression in the human brain and disruption in major depressive
disorder. Proc Natl Acad Sci U S A 110, 9950-9955.
59. Liu, S., Bubar, M. J., Lanfranco, M. F., Hillman, G. R., & Cunningham, K. A. (2007).
Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal
cortex: implications for understanding the neurobiology of addiction. Neuroscience
146, 1677-1688.
60. Machado-Vieira R. (2012). Tracking the impact of translational research in
psychiatry: state of the art and perspectives. J Transl Med 10, 175.
61. Maingret, F., Patel, A. J., Lesage, F., Lazdunski, M., & Honoré, E. (1999). Mechanoor acid stimulation, two interactive modes of activation of the TREK-1 potassium
channel. J Biol Chem 274, 26691-26696.
62. Maj, J., Bijak, M., Dziedzicka-Wasylewska, M., Rogoz, R., Rogóz, Z., Skuza, G., &
Tokarski, T. (1996). The effects of paroxetine given repeatedly on the 5-HT receptor
subpopulations in the rat brain. Psychopharmacology (Berl) 127, 73-82.
63. Matsukawa, J., Hori, Y., Nishida, H., Kajino, M., & Inatomi, N. (2011). A
comparative study on the modes of action of TAK-438, a novel potassium-competitive
acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem
Pharmacol 81, 1145-1151.
64. Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle, S., DaSilva, J., Wilson, A.
A., Rafi-Tari, S., Mayberg, H. S., & Kennedy, S. H. (2001). The effect of paroxetine
on 5-HT2A receptors in depression: an [(18)F] setoperone PET imaging study. Am J
Psychiatry 158, 78-85.
65. Miesenböck, G., De Angelis, D. A., & Rothman, J. E. (1998). Visualizing secretion
and synaptic transmission with pH-sensitive green fluorescent proteins. Nature 394,
192-195.
66. Millan, M. J., Dekeyne, A., & Gobert, A. (1998). Serotonin (5-HT)2C receptors
tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in
the frontal cortex in vivo. Neuropharmacology 37, 953-955.
67. Moore, T. J., Glenmullen, J., & Mattison, D. R. (2014). Reports of pathological
gambling, hypersexuality, and compulsive shopping associated with dopamine
receptor agonist drugs. JAMA Intern Med 174, 1930-1933.
68. Nagaoka, K., Nagashima, T., Asaoka, N., Yamamoto, H., Toda, C., Kayanuma, G.,
Siswanto, S., Funahashi, Y., Kuroda, K., Kaibuchi, K., Mori, Y., Nagayasu, K.,
Shirakawa, H., & Kaneko, S. (2021). Striatal TRPV1 activation by acetaminophen
ameliorates dopamine D2 receptor antagonist-induced orofacial dyskinesia. JCI
56
insight 6, e145632.
69. Nagashima, T., Shirakawa, H., Nakagawa, T., & Kaneko, S. (2016). Prevention of
antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction
followed by experimental exploration of the molecular mechanism. Sci Rep 6, 26375.
70. Nauczyciel, C., Le Jeune, F., Naudet, F., Douabin, S., Esquevin, A., Vérin, M.,
Dondaine, T., Robert, G., Drapier, D., & Millet, B. (2014). Repetitive transcranial
magnetic stimulation over the orbitofrontal cortex for obsessive-compulsive
disorder: a double-blind, crossover study. Transl Psychiatry 4, e436.
71. Nielen, M. M., den Boer, J. A., & Smid, H. G. (2009). Patients with obsessivecompulsive disorder are impaired in associative learning based on external feedback.
Psychol Med 39, 1519-1526.
72. Nirenberg, M. J., & Waters, C. (2006). Compulsive eating and weight gain related to
dopamine agonist use. Mov Disord 21, 524–529.
73. Nocjar, C., Alex, K. D., Sonneborn, A., Abbas, A. I., Roth, B. L., & Pehek, E. A. (2015).
Serotonin-2C and -2A receptor co-expression on cells in the rat medial prefrontal
cortex. Neuroscience 297, 22-37.
74. Nutt, D. J., Lingford-Hughes, A., Erritzoe, D., & Stokes, P. R. (2015). The dopamine
theory of addiction: 40 years of highs and lows. Nat Rev Neurosci 16, 305-312.
75. Olmos, A., Govindasamy, P. (2015) Propensity scores: a 729 practical introduction
using R. J Multidiscrip Eval 11: 68–88.
76. Opal, M. D., Klenotich, S. C., Morais, M., Bessa, J., Winkle, J., Doukas, D., Kay, L.
J., Sousa, N., & Dulawa, S. M. (2014). Serotonin 2C receptor antagonists induce fastonset antidepressant effects. Mol Psychiatry 19, 1106-1114.
77. Pallanti, S., Hollander, E., & Goodman, W. K. (2004). A qualitative analysis of
nonresponse: management of treatment-refractory obsessive-compulsive disorder. J
Clin Psychiatry 65 Suppl 14, 6–10.
78. Pallis, E., Vasilaki, A., Fehlmann, D., Kastellakis, A., Hoyer, D., Spyraki, C., &
Thermos, K. (2009). Antidepressants influence somatostatin levels and receptor
pharmacology in brain. Neuropsychopharmacology 34, 952-963.
79. Pauls, D. L., Abramovitch, A., Rauch, S. L., & Geller, D. A. (2014). Obsessivecompulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev
Neurosci 15, 410–424.
80. Perani, D., Garibotto, V., Gorini, A., Moresco, R. M., Henin, M., Panzacchi, A.,
Matarrese, M., Carpinelli, A., Bellodi, L., & Fazio, F. (2008). In vivo PET study of
5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive
disorder. NeuroImage 42, 306–314.
57
81. Pfeffer, C. K., Xue, M., He, M., Huang, Z. J., & Scanziani, M. (2013). Inhibition of
inhibition in visual cortex: the logic of connections between molecularly distinct
interneurons. Nat Neurosci 16, 1068-1076.
82. Porter, R. H., Benwell, K. R., Lamb, H., Malcolm, C. S., Allen, N. H., Revell, D. F.,
Adams, D. R., & Sheardown, M. J. (1999). Functional characterization of agonists at
recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J
Pharmacol 128, 13-20.
83. Posner, J., Marsh, R., Maia, T. V., Peterson, B. S., Gruber, A., & Simpson, H. B. (2014).
Reduced functional connectivity within the limbic cortico-striato-thalamo-cortical
loop in unmedicated adults with obsessive-compulsive disorder. Hum Brain Mapp
35, 2852-2860.
84. Qiu, S., Chen, T., Koga, K., Guo, Y. Y., Xu, H., Song, Q., Wang, J. J., Descalzi, G.,
Kaang, B. K., Luo, J. H., Zhuo, M., & Zhao, M. G. (2013). An increase in synaptic
NMDA receptors in the insular cortex contributes to neuropathic pain. Sci Signal 6,
ra34.
85. Radzicki, D., Yau, H. J., Pollema-Mays, S. L., Mlsna, L., Cho, K., Koh, S., & Martina,
M. (2013). Temperature-sensitive Cav1.2 calcium channels support intrinsic firing
of pyramidal neurons and provide a target for the treatment of febrile seizures. J
Neurosci 33, 9920-9931.
86. Remijnse, P. L., Nielen, M. M., van Balkom, A. J., Cath, D. C., van Oppen, P., Uylings,
H. B., & Veltman, D. J. (2006). Reduced orbitofrontal-striatal activity on a reversal
learning task in obsessive-compulsive disorder. Arch Gen Psychiatry 63, 1225-1236.
87. Renteria, R., Baltz, E. T., & Gremel, C. M. (2018). Chronic alcohol exposure disrupts
top-down control over basal ganglia action selection to produce habits. Nat Commun
9, 211.
88. Robbins, T. W., Vaghi, M. M., & Banca, P. (2019). Obsessive-Compulsive Disorder:
Puzzles and Prospects. Neuron 102, 27–47.
89. Rudy, B., Fishell, G., Lee, S., & Hjerling-Leffler, J. (2011). Three groups of
interneurons account for nearly 100% of neocortical GABAergic neurons. Dev
Neurobiol 71, 45-61.
90. Salas, R. E., Allen, R. P., Earley, C. J., & Gamaldo, C. E. (2009). A case of compulsive
behaviors observed in a restless legs syndrome patient treated with a dopamine
agonist. Sleep 32, 587–588.
91. Santana, N., & Artigas, F. (2017). Expression of Serotonin2C Receptors in Pyramidal
and GABAergic Neurons of Rat Prefrontal Cortex: A Comparison with Striatum.
Cereb Cortex 27, 3125-3139.
58
92. Santana, N., Bortolozzi, A., Serrats, J., Mengod, G., & Artigas, F. (2004). Expression
of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of
the rat prefrontal cortex. Cereb Cortex 14, 1100-1109.
93. Saxena, S., Brody, A. L., Maidment, K. M., Dunkin, J. J., Colgan, M., Alborzian, S.,
Phelps, M. E., & Baxter, L. R., Jr (1999). Localized orbitofrontal and subcortical
metabolic changes and predictors of response to paroxetine treatment in obsessivecompulsive disorder. Neuropsychopharmacology 21, 683-693.
94. Schirmbeck, F., Rausch, F., Englisch, S., Eifler, S., Esslinger, C., Meyer-Lindenberg,
A., & Zink, M. (2013). Differential effects of antipsychotic agents on obsessivecompulsive symptoms in schizophrenia: a longitudinal study. J Psychopharmacol 27,
349–357.
95. Siswanto, S., Yamamoto, H., Furuta, H., Kobayashi, M., Nagashima, T., Kayanuma,
G., Nagayasu, K., Imai, Y., & Kaneko, S. (2021). Drug Repurposing Prediction and
Validation From Clinical Big Data for the Effective Treatment of Interstitial Lung
Disease. Front Pharmacol 12, 635293.
96. Soto, E., Ortega-Ramírez, A., & Vega, R. (2018). Protons as Messengers of
Intercellular Communication in the Nervous System. Front Cell Neurosci 12, 342.
97. Starcevic, V., & Brakoulias, V. (2008). Symptom subtypes of obsessive-compulsive
disorder: are they relevant for treatment? Aust N Z J Psychiatry 42, 651-661.
98. Stein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R.
G., van den Heuvel, O. A., & Simpson, H. B. (2019). Obsessive-compulsive disorder.
Nat Rev Dis Primers 5, 52.
99. Takahashi, K., Dixon, D. B., & Copenhagen, D. R. (1993). Modulation of a sustained
calcium current by intracellular pH in horizontal cells of fish retina. J Gen Physiol
101, 695-714.
100. Tanaka, K., Dozono, N., Neyama, H., Nagai, J., Tsukahara, R., Nagayasu, K.,
Kaneko, S., & Ueda, H. (2021). Secreted PLA2-III is a possible therapeutic target to
treat neuropathic pain. Biochem Biophys Res Commun 568, 167–173.
101. Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E.
(2010). Systematic review of levodopa dose equivalency reporting in Parkinson's
disease. Mov Diord 25, 2649-2653.
102. Trujeque-Ramos, S., Castillo-Rolón, D., Galarraga, E., Tapia, D., Arenas-López, G.,
Mihailescu, S., & Hernández-López, S. (2018). Insulin Regulates GABAA ReceptorMediated Tonic Currents in the Prefrontal Cortex. Front Neurosci 12, 345.
103. Jaffe, A. E., Deep-Soboslay, A., Tao, R., Hauptman, D. T., Kaye, W. H., Arango, V.,
Weinberger, D. R., Hyde, T. M., & Kleinman, J. E. (2014). Genetic neuropathology of
59
obsessive psychiatric syndromes. Transl Psychiatry 4, e432.
104. Voon, V., Fernagut, P. O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos,
J. L., Obeso, J. A., & Bezard, E. (2009). Chronic dopaminergic stimulation in
Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 8,
1140–1149.
105. Voon, V., Baek, K., Enander, J., Worbe, Y., Morris, L. S., Harrison, N. A., Robbins, T.
W., Rück, C., & Daw, N. (2015). Motivation and value influences in the relative
balance of goal-directed and habitual behaviours in obsessive-compulsive disorder.
Transl Psychiatry 5, e670.
106. Wali, S., Shukr, A., Boudal, A., Alsaiari, A., & Krayem, A. (2015). The effect of
vitamin D supplements on the severity of restless legs syndrome. Sleep Breath 19,
579–583.
107. Wang, G. J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusil,
N., & Fowler, J. S. (2001). Brain dopamine and obesity. Lancet 357, 354-357.
108. Weintraub, D., Koester, J., Potenza, M. N., Siderowf, A. D., Stacy, M., Voon, V.,
Whetteckey, J., Wunderlich, G. R., & Lang, A. E. (2010). Impulse control disorders
in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67, 589595.
109. Welch, J. M., Lu, J., Rodriguiz, R. M., Trotta, N. C., Peca, J., Ding, J. D., Feliciano,
C., Chen, M., Adams, J. P., Luo, J., Dudek, S. M., Weinberg, R. J., Calakos, N., Wetsel,
W. C., & Feng, G. (2007). Cortico-striatal synaptic defects and OCD-like behaviours
in Sapap3-mutant mice. Nature 448, 894-900.
110. Yang, X., Li, Y., Sun, Y., Zhang, M., Guo, C., Mirza, I. A., & Li, Y. Q. (2018).
Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related
Diseases. Dig Dis Sci 63, 302-311.
111. Yokoyama, S., Tanaka, Y., Nakagita, K., Hosomi, K., & Takada, M. (2018). Bleeding
Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical
Cohort Study Using a Japanese Claims Database. Int J Med Sci 15, 1686–1693.
112. You, X., Wu, W., Xu, J., Jiao, Z., Ke, M., Huang, P., & Lin, C. (2020). Development of
a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole
Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment. J Clin
Pharmacol 60, 999-1010.
60
...
論文の公開元へ
